PBYI241018C2500
- 0.25
- -0.05-16.67%
Puma Biotechnology Newsroom
With A Return On Equity Of 18%, Has Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Management Done Well?
PUMA Explores Leather Vs Vegan Leather With Global Goals Ambassador
12 Health Care Stocks Moving In Tuesday's After-Market Session
PUMA Appoints Markus Neubrand as Chief Financial Officer
PUMA Transforms Product Campaign Development With Google Cloud's Generative AI
Puma Biotechnology (NASDAQ:PBYI) Investors Are Sitting on a Loss of 79% If They Invested Five Years Ago
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Puma Biotech Confirms Court Ruling on Patent Invalidity, Disagrees With Verdict
Federal Judge Rejects Patent Claims Supporting Puma Biotechnology's Breast Cancer Drug; Company Shares Down After Hours
Puma Biotechnology Quickly Drops After Patents for Tagrisso Ruled Invalid
Puma Biotechnology's (NASDAQ:PBYI) Earnings Offer More Than Meets The Eye
Puma's Catalogue Remains Attractive Despite Woes -- Market Talk
Pfizer Tagrisso Patent Case Against AstraZeneca Upheld by Judge
Express News | Puma Biotechnology Inc - Wyeth Filed Motion Requesting Supplemental Damages for Past Infringement From Jan 1, Through Date of Judgment
Express News | Puma Biotechnology Inc - AstraZeneca Has Filed a Motion Challenging Jury's Aug 6 Verdict & Requesting New Trial
Express News | Puma Biotechnology- on Aug 6 Court Found AstraZeneca Had Not Proved Claim That Wyeth's Asserted Patents Were Invalid as Indefinite
There's No Escaping Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Muted Revenues Despite A 37% Share Price Rise
Puma Narrows FY24 Operating Result Outlook; Sales Expectations Maintained
Puma's Performance in EMEA Could Raise Concerns -- Market Talk
Puma Shares Slump After Sportswear Group Trims Profit Forecasts